Virupaksha Organics Ltd operates with world-class infrastructure at its manufacturing units in Kazipally and Pashamylaram, Telangana. These facilities form the backbone of the company’s production capacity, enabling it to deliver high-quality Active Pharmaceutical Ingredients (APIs) to customers across the globe. Strategically located near Hyderabad, India’s pharmaceutical hub, the sites are fully equipped to meet large-scale production requirements while maintaining the highest standards of quality and safety.
The Kazipally unit has earned recognition for its robust capabilities in producing APIs under strict Good Manufacturing Practices (GMP). With state-of-the-art equipment, automated process controls, and advanced analytical labs, the plant ensures precision and consistency in every batch produced. Similarly, the Pashamylaram unit complements this strength with scalable production systems, modern quality control laboratories, and a focus on sustainable operations such as energy conservation and waste reduction.
Both plants have successfully undergone audits by global regulatory agencies, including the US FDA and European authorities, making Virupaksha a trusted partner for pharmaceutical companies worldwide. Compliance with stringent international standards demonstrates the company’s commitment to patient safety and reliability. In addition, dedicated R&D teams at these facilities ensure that process improvements and new molecules are introduced seamlessly into commercial production.
Safety and sustainability are at the core of operations. With Zero Liquid Discharge (ZLD) systems and eco-friendly process modifications, Virupaksha is minimizing its environmental impact while maximizing efficiency. These green initiatives align with global expectations of sustainable pharmaceutical manufacturing.
Together, the Kazipally and Pashamylaram units represent Virupaksha’s commitment to quality, compliance, and innovation. By investing continuously in infrastructure, talent, and technology, the company is well-positioned to expand its portfolio and reinforce its leadership in the pharmaceutical industry.
